New Cancer Cure-Bio Co.,Ltd.
π°π·South Korea
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)The KN510713 Study in Combination With mFOLFIRINOX
Not Applicable
Not yet recruiting
- Conditions
- Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- New Cancer Cure-Bio Co.,Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT07114861
- Locations
- π°π·
National Cancer Center, Goyang-si, Korea, Republic of
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: KN510 120mg/day + KN713 120mg/dayDrug: KN510 60mg/day + KN713 60mg/dayDrug: KN510 120mg/day + KN713 60mg/dayDrug: KN510 120mg/day + KN713 90mg/day
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- New Cancer Cure-Bio Co.,Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06012708
- Locations
- π°π·
National Cancer Center, Goyang-si, Korea, Republic of
News
No news found